美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

SPDR S&P Biotech ETF

124.23

+4.693.92%

成交量：661.38萬

成交額：8.19億

市值：77.02億

市盈率：6.81

高：124.69

開：121.24

低：121.14

收：119.54

52周最高：132.09

52周最低：66.66

股本：6,200.00萬

流通股本：6,200.00萬

量比：1.57

換手率：10.67%

股息：0.44

股息率：0.36%

每股收益(TTM):18.23

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

中銀基金青黃不接，新人李文廣成「帶頭大哥」

醫療保健板塊動態聚焦：市場觀點速遞

生物醫藥板塊午後再度拉升靈康藥業觸及漲停

每日经济新闻

AH股高開低走：創業板跌超2%，生物醫藥拉升，光伏大跌，恒科指轉跌，新消費反彈、老鋪黃金漲8%

华尔街见闻

賠付率低位徘徊，短期健康險性價比成謎

21世纪经济报道

派格生物醫藥-B(02565)發布年度業績研發開支5038.7萬元已成功構建覆蓋七款針對慢性疾病領域的在研藥物管線矩陣

中國人民保險集團趙鵬：推動商業醫療保險快賠直賠，推廣一站式直賠服務

羅氏集團施萬：中國已具備良好的商業健康保險基礎

跑出生物醫藥創新加速度——來自上海市的調查

創新「飛輪」加速轉動：上海生物醫藥產業何以領跑全國？

深圳市亞輝龍生物科技被罰400萬，責任人共被罰350萬，涉信披不準確

聚焦鋼鐵、化工、生物醫藥等重點行業河北將培育一批工業大模型

太平人壽業務範圍增加「團體長期健康保險」業務

醫療保健行業動態：市場焦點對話

派格生物醫藥-B升逾10%

每日经济新闻

【券商聚焦】中國銀河：「十五五」首次將生物醫藥列為國家新興支柱產業，持續發力研發創新

醫療保健板塊綜述：市場觀點

航空航天、新能源、生物醫藥三箭齊發四川什邡工業衝刺「開門紅」

中銀醫療保健混合A基金經理變動：鄭寧不再擔任該基金基金經理

再迎阿斯利康重磅佈局！浦東生物醫藥產業究竟有啥「磁場效應」？

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/XBI/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"XBI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBI\",,,,,undefined,":{"symbol":"XBI","market":"US","secType":"STK","nameCN":"SPDR S&P Biotech ETF","latestPrice":124.23,"timestamp":1774454834708,"preClose":119.54,"halted":0,"volume":6613754,"delay":0,"changeRate":0.03923372929563324,"floatShares":62000000,"shares":62000000,"eps":18.23,"marketStatus":"交易中","change":4.69,"latestTime":"03-25 12:07:19 EDT","open":121.24,"high":124.6875,"low":121.135,"amount":818746739.923224,"amplitude":0.029718,"askPrice":124.27,"askSize":290,"bidPrice":124.25,"bidSize":200,"shortable":3,"etf":1,"ttmEps":18.23,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1774468800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":119.54,"sharesOutstanding":63325000,"nav":121.723084,"aum":7546831221.25,"dividendRate":0.00356,"bidAskSpread":0.000171,"preHourTrading":{"tag":"盘前","latestPrice":121.1,"preClose":119.54,"latestTime":"09:29 EDT","volume":18915,"amount":2294133.20175,"timestamp":1774445399999,"change":1.56,"changeRate":0.01305,"amplitude":0.01397},"postHourTrading":{"tag":"盘后","latestPrice":120.5,"preClose":119.54,"latestTime":"19:55 EDT","volume":250294,"amount":29970967.9089,"timestamp":1774396542259,"change":0.96,"changeRate":0.008031,"amplitude":0.014723},"volumeRatio":1.573131,"optionData":{"bulkOrders":[{"symbol":"XBI","call":false,"expireDate":1778817600000,"strike":"110.0","timestamp":1774446035714,"price":1.87,"volume":6135,"amount":1147245,"type":"+"},{"symbol":"XBI","call":false,"expireDate":1778817600000,"strike":"95.0","timestamp":1774446035714,"price":0.24,"volume":6135,"amount":147240,"type":"-"}]},"impliedVol":0.3491,"impliedVolPercentile":0.8327},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBI\",,,,,undefined,":{"symbol":"XBI","floatShares":62000000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.573131,"shares":62000000,"dividePrice":0.4423,"high":124.6875,"amplitude":0.029718,"preClose":119.54,"low":121.135,"week52Low":66.66,"pbRate":"--","week52High":132.09,"institutionHeld":0.8511,"latestPrice":124.23,"committee":-0.183673,"eps":18.23,"divideRate":0.00356,"volume":6613754,"delay":0,"ttmEps":18.23,"open":121.24,"prevYearClose":121.93,"prevWeekClose":120.31,"prevMonthClose":127.37,"prevQuarterClose":121.93,"fiveDayClose":121.11,"twentyDayClose":128.28,"sixtyDayClose":124.98},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XBI\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"XBI","amount":0.406564,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-24"},{"date":"2025-09-22","symbol":"XBI","amount":0.02665,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-24","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-24"},{"date":"2025-06-23","symbol":"XBI","amount":0.007295,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-25","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-25"},{"date":"2025-03-24","symbol":"XBI","amount":0.00525,"announcedDate":"2025-03-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-24","defaultRemindTime":1742823000000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-26","payableDate":"2025-03-24","currency":"USD","dateTimestamp":1742788800000,"payDate":"2025-03-26"},{"date":"2024-12-23","symbol":"XBI","amount":0.002687,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XBI\",market:\"US\",,,undefined,":[{"executeDate":"2016-06-17","recordDate":"2016-06-21","paymentDate":"2016-06-27","value":0.045491,"currency":"USD"},{"executeDate":"2016-09-16","recordDate":"2016-09-20","paymentDate":"2016-09-26","value":0.031139,"currency":"USD"},{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-27","value":0.01831,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-27","value":0.019702,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-26","value":0.110135,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XBI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XBI\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622502641","title":"中銀基金青黃不接，新人李文廣成「帶頭大哥」","url":"https://stock-news.laohu8.com/highlight/detail?id=2622502641","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622502641?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 16:55","pubTimestamp":1774428900,"startTime":"0","endTime":"0","summary":"　　在新掌门人刘信群上任三个月后，银行系老牌公募中银基金“权益一哥”郑宁卸任了所有在管4只产品基金经理职务。　　据中银基金近日公告，因个人原因，郑宁卸任中银创新医疗、中银医疗保健、中银港股通医药、中银大健康的基金经理。　　在中银基金，郑宁成为基金经理，截至离任，基金经理从业年限也不满4年。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjyj/2026-03-25/doc-inhseyvu6769992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LABU","BK4581","VXUS","BK4585","XLV","XBI","BK4588"],"gpt_icon":0},{"id":"1132755020","title":"醫療保健板塊動態聚焦：市場觀點速遞","url":"https://stock-news.laohu8.com/highlight/detail?id=1132755020","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132755020?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 16:24","pubTimestamp":1774340681,"startTime":"0","endTime":"0","summary":"分析师在报告中称，丁腈橡胶供应紧张以及丁腈和天然橡胶价格攀升可能对销量构成压力，但灵活的生产线或可转向生产天然橡胶手套。他们预计，下半财年利润率将改善，从而抵消上半年的疲软表现。此外，该股当前估值看似不高，且具备应对市场波动的良好能力。CGS国际维持对顶级手套的\"增持\"评级，目标价保持在0.67林吉特。股价持平于0.56林吉特。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LU0203347892.USD","LU1791807156.HKD","LU1496350171.SGD","LU0321505868.SGD","LU1069347547.HKD","BK4553","LU0128525689.USD","LU0648000940.SGD","LU1506573853.SGD","IE00BZ1G4Q59.USD","IE00BLSP4239.USD","LU1668664300.SGD","LU0053666078.USD","LU0098860793.USD","LU0417517546.SGD","LU0310800965.SGD","LU1366192091.USD","LU0256863902.USD","BK4534","LU0106831901.USD","LU0234572021.USD","LU0211331839.USD","LU1718418525.SGD","LU0320765646.SGD","IE0001KFT4U8.USD","BK4207","IE00B19Z3B42.SGD","LU0477156953.USD","LU1496350502.SGD","LU0306806265.USD","LU0256863811.USD","LU0640476718.USD","LABU","LU1880398554.USD","XLV","LU1201861165.SGD","LU1894683348.USD","IE0002270589.USD","IE0034235188.USD","LU0052756011.USD","LU2129689431.USD","LU1880398471.USD","LU0203345920.USD","LU2129689514.USD","LU0170899867.USD","LU0321505439.SGD","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","LU2129689605.HKD","BK4585","LU0787776722.HKD","BK4559","IE00BFXG1179.USD","LU0980610538.SGD","LU0130517989.USD","LU0070302665.USD","LU1035773651.USD","LU0314106906.USD","LU1883839398.USD","BAC","LU1363072403.SGD","IE00BBT3K403.USD","LU1074936037.SGD","LU1894683264.USD","LU1804176565.USD","LU0648001328.SGD","LU0477156797.USD","LU1162221912.USD","LU0234570918.USD","LU0130102774.USD","LU2133065610.SGD","LU0130518102.USD","BK4588","LU0149725797.USD","LU0971096721.USD","LU2265009873.SGD","LU1280957306.USD","LU0130103400.USD","LU1267930227.SGD","IE00B1BXHZ80.USD","LU0208291251.USD","BK4504","LU0868494617.USD","LU0306807586.USD","LU0683600562.USD","LU0320765489.SGD","XBI","IE00BLSP4452.SGD","LU1201861249.SGD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2621055153","title":"生物醫藥板塊午後再度拉升 靈康藥業觸及漲停","url":"https://stock-news.laohu8.com/highlight/detail?id=2621055153","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621055153?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 13:17","pubTimestamp":1774329420,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月24日，生物医药板块午后再度拉升，灵康药业（维权）触及涨停，迪哲医药、共同药业、苑东生物、诚意药业跟涨。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-24/doc-inhsaeyx3555839.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-24/doc-inhsaeyx3555839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["161726","BK4581","XBI","BK0033","BK0239","BK4585","BK4588","399441","BK0056","603669"],"gpt_icon":0},{"id":"2621310810","title":"AH股高開低走：創業板跌超2%，生物醫藥拉升，光伏大跌，恒科指轉跌，新消費反彈、老鋪黃金漲8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621310810","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621310810?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 10:16","pubTimestamp":1774318613,"startTime":"0","endTime":"0","summary":"存储芯片概念盘中震荡下挫，普冉股份跌超10%，太极实业、兆易创新、朗科科技、北京君正、江波龙等跟跌。军工板块集体拉升，长城军工涨停，北方长龙、江航装备、捷强装备、内蒙一机、国科军工跟涨。油气股开盘后加速跳水，和顺石油跌超7%，洲际油气跌近7%，中国石油、中国石化、中国海油均跌超2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3768220","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"79ce7c981e6853108578199dad810001","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3768220","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000300.SH","399441","BK1227","XBI","BK4581","000905.SH","06181","000001.SH","159982","512510","SGXZ90724238.SGD","515890","399006","399300","161726","BK4588","399001","512880","159915","159967","SG9999001051.SGD","510880","510300","BK1544","000688.SH","BK4585"],"gpt_icon":1},{"id":"2621705056","title":"賠付率低位徘徊，短期健康險性價比成謎","url":"https://stock-news.laohu8.com/highlight/detail?id=2621705056","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621705056?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 20:41","pubTimestamp":1774269660,"startTime":"0","endTime":"0","summary":"　　近年来，随着国民健康保障意识的全面觉醒与多层次医疗保障体系的持续完善，以“百万医疗险”为代表的个人短期健康险迎来了爆发式的规模扩张。　　近期，21世纪经济报道记者统计了59家财产险公司2025年全年个人短期健康险综合赔付率数据，并对比了2024年的情况。数据显示，59家财险公司2025年全年短期健康险综合赔付率中位数仅为41.09%，其中34家公司赔付率下降，占比近六成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/money/insurance/bxdt/2026-03-23/doc-inhrysxp7855345.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxdt/2026-03-23/doc-inhrysxp7855345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4581","BK4588","BK4585","XLV","XBI","LABU"],"gpt_icon":0},{"id":"2621776330","title":"派格生物醫藥-B(02565)發布年度業績 研發開支5038.7萬元 已成功構建覆蓋七款針對慢性疾病領域的在研藥物管線矩陣","url":"https://stock-news.laohu8.com/highlight/detail?id=2621776330","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621776330?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 16:38","pubTimestamp":1774255101,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B 发布截至2025年12月31日止年度业绩，该集团取得其他净收入18.9万元;研发开支5038.7万元;每股基本亏损0.55元。截至本公告日期，我们在于美国及中国推进技术创新、产品管线及业务营运方面取得重大进展。截至本公告日期，派格生物已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵。随着核心产品派达康于2025年11月成功获得上市批准，集团将全面推进其在中国市场的商业化落地工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161726","399441","BK1161","XBI","BK4585","BK4588","02565","BK4581"],"gpt_icon":0},{"id":"2621872654","title":"中國人民保險集團趙鵬：推動商業醫療保險快賠直賠，推廣一站式直賠服務","url":"https://stock-news.laohu8.com/highlight/detail?id=2621872654","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621872654?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 11:05","pubTimestamp":1774235100,"startTime":"0","endTime":"0","summary":"　　中国发展高层论坛2026年年会于3月22日至23日在北京举行。在“健康中国2030”与大健康产业发展专题研讨会上，中国人民保险集团股份有限公司总裁赵鹏表示，保险作为健康中国建设的重要参与力量，在保障人民群众病有所治、药有所保、健康生活等方面，有着不可替代的价值和功能。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/meeting/2026-03-23/doc-inhrxvtw1265615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01339","XLV","LU1282651048.USD","BK4585","BK4581","LU1224444064.USD","LU1522347837.USD","BK1550","BK1521","LU1675838814.USD","BK1127","BK4588","LABU","LU0293314216.USD","XBI","LU1497734951.SGD","LU1634259557.SGD","LU1282651121.HKD","LU1497733557.USD","LU1497733631.SGD","LU1634259391.SGD"],"gpt_icon":0},{"id":"2621725011","title":"羅氏集團施萬：中國已具備良好的商業健康保險基礎","url":"https://stock-news.laohu8.com/highlight/detail?id=2621725011","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621725011?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 10:54","pubTimestamp":1774234440,"startTime":"0","endTime":"0","summary":"　　中国发展高层论坛2026年年会于3月22日至23日在北京举行。在“健康中国2030”与大健康产业发展专题研讨会上，罗氏集团董事会主席施万指出，有两大核心因素推动中国成为全球重要的生命科学枢纽。中国在基础科学、教育、顶级大学、顶级医院等领域的远见性投资，为企业创新奠定了坚实基础。　　施万表示，中国当前也面临类似挑战。预算赤字、多领域资金竞争以及人口老龄化，但中国拥有欧洲不具备的独特机遇，商业保险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/meeting/2026-03-23/doc-inhrxvtz4224034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LABU","BK4581","BK4588","XBI","BK4585","XLV"],"gpt_icon":0},{"id":"2621741249","title":"跑出生物醫藥創新加速度——來自上海市的調查","url":"https://stock-news.laohu8.com/highlight/detail?id=2621741249","media":"经济日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621741249?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 05:41","pubTimestamp":1774215662,"startTime":"0","endTime":"0","summary":"今年的《政府工作报告》首次将生物医药纳入新兴支柱产业范畴，对“推动创新药和医疗器械高质量发展”也作出相应部署。在生物医药这条赛道，上海率先跑出了加速度，积极支持生物医药产业全链条创新发展，“走出去”“引进来”的步伐越来越稳，来自上海的创新药械正加速构建全球竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603233679851739.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["399441","BK4581","161726","BK4585","BK4588","XBI"],"gpt_icon":0},{"id":"2621748296","title":"創新「飛輪」加速轉動：上海生物醫藥產業何以領跑全國？","url":"https://stock-news.laohu8.com/highlight/detail?id=2621748296","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621748296?lang=zh_tw&edition=fundamental","pubTime":"2026-03-22 23:51","pubTimestamp":1774194660,"startTime":"0","endTime":"0","summary":"生物医药被称为“永不衰落的朝阳产业”——它既是守护人类健康的终极防线，也是国家科技硬实力的重要体现。而上海以其不可忽视的行业地位，被视作观察中国生物医药产业的一座样本城市。30年前，上海的本土医药企业主要以生产仿制药为主，原研创新药严重依赖外资企业。如今，记者从上海市科委获悉，2025年上海生物医药产业规模首次突破万亿元大关，生物医药制造业产值近2100亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603223679831457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4581","161726","399441","XBI","BK4588","BK4585"],"gpt_icon":0},{"id":"2621676640","title":"深圳市亞輝龍生物科技被罰400萬，責任人共被罰350萬，涉信披不準確","url":"https://stock-news.laohu8.com/highlight/detail?id=2621676640","media":"蓝鲸财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621676640?lang=zh_tw&edition=fundamental","pubTime":"2026-03-21 12:47","pubTimestamp":1774068437,"startTime":"0","endTime":"0","summary":"蓝鲸新闻3月21日讯，近日，深圳证监局发布行政监管措施决定书，剑指深圳市亚辉龙生物科技股份有限公司及其实际控制人胡鹍辉、董事会秘书王鸣阳。胡鹍辉作为亚辉龙董事长，王鸣阳作为亚辉龙董事会秘书，对上述违法行为负有责任。对此，深圳证监局决定对深圳市亚辉龙生物科技股份有限公司责令改正，给予警告，并处以400万元罚款；对胡鹍辉给予警告，并处以200万元罚款；对王鸣阳给予警告，并处以150万元罚款。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1774001481558505859","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["XBI","BK4588","159837","BK4581","BK4585","BK0239","688575"],"gpt_icon":0},{"id":"2621506287","title":"聚焦鋼鐵、化工、生物醫藥等重點行業 河北將培育一批工業大模型","url":"https://stock-news.laohu8.com/highlight/detail?id=2621506287","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621506287?lang=zh_tw&edition=fundamental","pubTime":"2026-03-21 06:57","pubTimestamp":1774047420,"startTime":"0","endTime":"0","summary":"在化工行业，河北聚焦安全生产、工艺控制、配方优化、环保监测等场景，培育智能控制大模型、安全预警大模型。在生物医药行业，河北针对药物研发、质量追溯、生产管控、临床辅助等场景，培育药物研发大模型、智能质检大模型。在机器人行业，河北针对运动控制、视觉识别、人机协作、自主决策等场景，培育运动控制大模型、多模态感知大模型。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-03-21/doc-inhrswxz7526058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4581","XBI","161726","BK4588","399441","BK4585"],"gpt_icon":0},{"id":"2620731854","title":"太平人壽業務範圍增加「團體長期健康保險」業務","url":"https://stock-news.laohu8.com/highlight/detail?id=2620731854","media":"金融一线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620731854?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 21:24","pubTimestamp":1774013040,"startTime":"0","endTime":"0","summary":"3月20日金融一线消息，国家金融监督管理总局近日发布《关于太平人寿保险有限公司变更业务范围的批复》，同意太平人寿业务范围增加“团体长期健康保险”业务。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：曹睿潼","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jryx/insurance/2026-03-20/doc-inhrrzut6676154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","XLV","LABU","XBI","BK4581","BK4585"],"gpt_icon":0},{"id":"1199016154","title":"醫療保健行業動態：市場焦點對話","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016154","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199016154?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 16:29","pubTimestamp":1773995356,"startTime":"0","endTime":"0","summary":"医疗保健板块最新市场对话精选。管理层在分析师会议上对前景持谨慎态度，担忧地缘政治冲突可能波及泰国经济及本土患者流量。该分析师预估，这家泰国医院今年住院收入可能下降5%。格林威治时间22:06 - 西格玛医疗股价近期跌至逾一年低点，促使杰富瑞集团转而看好这家药房运营商的股票。杰富瑞同时预期西格玛批发业务将改善，将其评级从\"持有\"上调至\"买入\"。西格玛周四收报2.66澳元，低于杰富瑞3.05澳元的目标价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4581","BK4588","BK6506","BK6079","XBI","BK4585","H02.SI","SG9999006266.SGD","IE0031814969.USD","XLV"],"gpt_icon":0},{"id":"2620209854","title":"派格生物醫藥-B升逾10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620209854","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620209854?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 10:51","pubTimestamp":1773975087,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月20日，派格生物医药-B(02565.HK)涨超10%，截至发稿，涨10.21%，报61.55港元，成交额2519.24万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603203678545515.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603203678545515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","XBI","161726","BK4585","BK4581","02565","399441","BK4588"],"gpt_icon":0},{"id":"2620203185","title":"【券商聚焦】中國銀河：「十五五」首次將生物醫藥列為國家新興支柱產業，持續發力研發創新","url":"https://stock-news.laohu8.com/highlight/detail?id=2620203185","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620203185?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 09:23","pubTimestamp":1773969824,"startTime":"0","endTime":"0","summary":"“十四五”规划重点关注医药创新产品产业化、医药产业化技术攻关、疫苗和短缺药品供应保障、产品质量升级、医药工业绿色低碳等五大工程，成效斐然，中国创新药获批上市数量由2015年的11款提升至2024年的92款，2024年共有22款国产化药和17款国产生物药获批上市，国产创新药占比提升至42%。“十五五”规划提出健全医疗、医保、医药协同发展和治理机制，生物医药产业首次被列为国家“新兴支柱产业”，战略定位进一步提升。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976888","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0307460666.USD","LU0348766576.USD","BK4588","LU2778985437.USD","LU2045819591.USD","02359","161726","XBI","HK0000306701.USD","LU2328871848.SGD","02696","601881","HK0000320223.HKD","LU2476274308.USD","06881","LU0348825331.USD","BK1141","BK1588","HK0000306685.HKD","02268","09995","LU2476274720.SGD","BK4585","LU0561508036.HKD","LU0708995583.HKD","09926","LU0348767384.USD","LU1720050803.USD","LU0417516571.SGD","LU1770034418.SGD","06160","LU0348735423.USD","399441","LU2125910500.SGD","LU2242644610.SGD","SG9999014674.SGD","LU0052750758.USD","BK1147","BK1161","BK1564","LU0196878994.USD","IE00B543WZ88.USD","LU0540923850.HKD","06990","BK4581","LU0588546209.SGD","02162","LU1969619763.USD","BK0276"],"gpt_icon":0},{"id":"1139305073","title":"醫療保健板塊綜述：市場觀點","url":"https://stock-news.laohu8.com/highlight/detail?id=1139305073","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139305073?lang=zh_tw&edition=fundamental","pubTime":"2026-03-19 16:25","pubTimestamp":1773908729,"startTime":"0","endTime":"0","summary":"最新发布的医疗保健板块市场观点。0128 GMT——马来亚银行投资银行分析师Wong Wei Sum在一份报告中指出，中东冲突导致的合成橡胶市场短期中断可能对顶级手套有利。她表示，这是因为该公司能够同时生产丁腈手套和天然橡胶手套，为价格敏感的客户提供了替代选择。她表示，近期丁腈乳胶价格的上涨和供应中断可能会引发客户的复杂反应，包括恐慌性购买、暂时延迟订单以及转向天然橡胶手套。该股下跌1.7%，报0.56令吉。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4581","BK4588","XBI","BK6103","BK6511","TFmain","BK4585","XLV","BVA.SI"],"gpt_icon":0},{"id":"2620188290","title":"航空航天、新能源、生物醫藥三箭齊發 四川什邡工業衝刺「開門紅」","url":"https://stock-news.laohu8.com/highlight/detail?id=2620188290","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620188290?lang=zh_tw&edition=fundamental","pubTime":"2026-03-19 10:45","pubTimestamp":1773888300,"startTime":"0","endTime":"0","summary":"“镧影R6000”的载人版已于今年2月通过设计方案评审，研发团队计划于今年6月启动倾转模态科研试飞。目前，企业已接到多个订单，正在加紧生产中。欣旺达德阳基地是集研发、制造、销售于一体的现代化新能源产业基地，总投资100亿元。新年以来，什邡工业企业以“满格电”“冲刺跑”状态，奋力决战“开门红”。“1～2月，什邡规上工业企业实现产值123亿元，增长11.2%。”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/t/2026-03-19/doc-inhrnvix8747648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159227","BK4581","161726","BK4585","BK4588","000941.SH","160640","159875","399441","UFO","BK4564","399941","XBI"],"gpt_icon":0},{"id":"2620341297","title":"中銀醫療保健混合A基金經理變動：鄭寧不再擔任該基金基金經理","url":"https://stock-news.laohu8.com/highlight/detail?id=2620341297","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620341297?lang=zh_tw&edition=fundamental","pubTime":"2026-03-19 10:02","pubTimestamp":1773885720,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年3月19日，中银医疗保健混合(005689)发布公告，郑宁不再担任该基金基金经理，离任日期为2026年3月19日，变更后中银医疗保健混合(005689)的基金经理为李文广。截止2026年3月18日，中银医疗保健混合净值为3.3907，较上一日上涨1.47%，近一年上涨43.04%。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260319/32080642.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LABU","BK4588","BK4581","XLV","BK4585","XBI"],"gpt_icon":0},{"id":"2620292921","title":"再迎阿斯利康重磅佈局！浦東生物醫藥產業究竟有啥「磁場效應」？","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292921","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620292921?lang=zh_tw&edition=fundamental","pubTime":"2026-03-19 09:34","pubTimestamp":1773884072,"startTime":"0","endTime":"0","summary":"3月19日，张江科学城再添全球生物医药产业重磅布局——阿斯利康正式宣布在此建设细胞疗法创新中心。这个覆盖早期研究、病毒载体开发、临床生产及注册支持的全链条创新平台，将成为阿斯利康全球细胞疗法版图的关键枢纽，标志着中国在全球下一代细胞治疗领域的创新地位再获提升。生物医药产业是上海三大先导产业之一，也是新一轮科技革命和竞争的焦点赛道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://biz.eastmoney.com/a/202603193676916419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["161726","LU0058720904.USD","LU2456880835.USD","LU0320765992.SGD","BK4585","AZN","399441","LU0889565916.HKD","LU1829250122.USD","LU0109394709.USD","BK4581","BK4588","IE00B3T34201.USD","LU2462157665.USD","LU2236285917.USD","LU2417539215.USD","BK4568","XBI","BK4007","LU0289739699.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":198,"code":"91000000","status":"200"}]}}